{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"Home","text":""},{"location":"endoscopy/anticoagulation/","title":"Anticoagulation","text":"<p>Date: 26-10-2019</p>"},{"location":"endoscopy/anticoagulation/#warfarin-and-noacs","title":"Warfarin and NOACs","text":""},{"location":"endoscopy/anticoagulation/#anti-platelets","title":"Anti-platelets","text":""},{"location":"endoscopy/anticoagulation/#aspirin","title":"Aspirin","text":"<p>Aspirin interruption in patients for secondary prevention is associated with 3x increased CV events, and 70% of these events occurs within 7\u201310 days after interruption. Be very careful in stopping aspirin!</p>"},{"location":"endoscopy/anticoagulation/#references","title":"References","text":"<ol> <li>BSG Anticoagulation Guidelines 2016</li> </ol>"},{"location":"endoscopy/barretts/","title":"Barrett's Oesophagus","text":"<p>Date: 28-10-2019</p>"},{"location":"endoscopy/barretts/#diagnosis","title":"Diagnosis","text":"<ul> <li>&gt;1cm length from GOJ of confirmed intestinal metaplasia on biopsy</li> <li>High definition endoscopy (other modalities not advised)</li> <li>Random 4 quadrant biopsies every 2cm</li> </ul>"},{"location":"endoscopy/barretts/#general-flowchart","title":"General Flowchart","text":"<p>ESGE Position:</p> <ul> <li> <p>&lt;1cm - no surveillance</p> </li> <li> <p>1-3cm - 5 years</p> </li> <li>3-10cm - 3 years</li> <li>&gt;10cm - Barrett's centre</li> <li>No surveillance if age&gt;75</li> </ul> <p></p> <p>Flowchart from 2013 BSG guidelines</p>"},{"location":"endoscopy/barretts/#dysplasia-flowchart","title":"Dysplasia Flowchart","text":"<p>Indefinite for dysplasia requires 6-month follow-up. 6\u2005months for LGD. If LGD is also found at follow-up endoscopy, even if not consecutive, provided that the diagnosis of dysplasia on two occasions is confirmed by two independent GI pathologists (ideally from a different institution), endoscopic ablation should be considered. HGD also needs to be confirmed by a second GI pathologist.</p> <p>Consensus diagnosis of LGD by independent pathologists correlates with a significant risk of progression to HGD/cancer and RFA significantly reduces this risk. (3)</p>"},{"location":"endoscopy/barretts/#treatment","title":"Treatment","text":"<ul> <li>Prophylactic endotherapy for non-dysplasia not advised (0.3% risk of progression to cancer/year)</li> <li>Indefinite for dysplasia - repeat in 6 months, if repeat has not dysplasia no surveillance</li> <li>Low grade dysplasia - repeat in 6 months, if LGD at repeat for RFA; if no LGD repeat in 6 months and if ok resume as above</li> <li>High grade dysplasia - RFA</li> <li>T1a adenocarcinoma - EMR</li> </ul> <p>Note: NICE guidelines are being updated as of 2018</p>"},{"location":"endoscopy/barretts/#read-more","title":"Read More","text":"<ol> <li>Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. 2017</li> <li>BSG guidelines on the diagnosis and management of Barrett's oesophagus 2015</li> <li>Revised BSG guidelines 2017</li> </ol>"},{"location":"endoscopy/colonoscopy_surveillance/","title":"Colonoscopy Surveillance","text":"<p>Date: 26-10-2019</p>"},{"location":"endoscopy/colonoscopy_surveillance/#2020-guidelines","title":"2020 Guidelines","text":""},{"location":"endoscopy/colonoscopy_surveillance/#ibd","title":"IBD","text":""},{"location":"endoscopy/colonoscopy_surveillance/#pouch-surveillance","title":"Pouch Surveillance","text":""},{"location":"endoscopy/colonoscopy_surveillance/#pre-2020-guidelines","title":"Pre-2020 Guidelines","text":""},{"location":"endoscopy/colonoscopy_surveillance/#references","title":"References","text":"<ol> <li>Atkin WS, Saunders BPSurveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002;51:v6-v9.</li> <li>BSG/ACPGBI guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) 2010</li> <li>BSG/ACPGBI/PHE Post-polypectomy and post-colorectal cancer resection surveillance guidelines 2019</li> </ol>"},{"location":"endoscopy/gastric_ulcer_protocol/","title":"Gastric Ulcer Protocol","text":"<p>Reference data/paper: Here</p>"},{"location":"endoscopy/gastric_ulcer_protocol/#initial-endoscopy","title":"Initial Endoscopy","text":"<p>When a gastric ulcer is found on initial endoscopy it is essential that:</p> <ol> <li>A description of the ulcer is provided in the report including if it looks benign or malignant, an estimate of the ulcer size and its location</li> <li>All gastric ulcers should be biopsied (at least x6). If there is concern that biopsy could provoke any bleeding (e.g. in inpatient bleeders), a repeat OGD for biopsies should be scheduled ideally prior to discharge</li> <li>A CLO test is taken</li> <li>A malignancy risk score is calculated (see table below)</li> </ol> <p>On receiving the biopsy results:</p> <ol> <li> <p>If the histology it not concerning for malignancy/dysplasia there is no need to arrange a follow-up endoscopy providing:</p> </li> <li> <p>The ulcer appeared benign macroscopically</p> </li> <li>Any symptoms settle</li> <li>There is no concern about rarer causes of ulceration such as gastric Crohn\u2019s</li> <li> <p>The ulcer risk score is &lt;3</p> </li> <li> <p>If there were concerning macroscopic appearances with benign appearing biopsies an 8 week repeat OGD should be arranged.</p> </li> </ol> <p>Ulcer risk score calculation:</p> <p>An ulcer risk score of &lt;3 has an NPV 97.4% without taking into account if the ulcer appears benign or not. It is considered an extra layer of safety to ensure malignancies are not missed despite the apparent 100% NPV of the combination of benign macroscopic and benign microscopic appearances.</p>"},{"location":"endoscopy/haggitt/","title":"Haggitt Staging for Polyp Resection","text":"<p>Date: 29-10-2019</p> <p></p> <ul> <li>Haggitt proposed a classification system in 1985</li> <li>Level 4 associated with death and lymph spread</li> </ul>"},{"location":"endoscopy/haggitt/#kikuchi-level","title":"Kikuchi Level","text":"<ul> <li>Kikuchi proposed further classification in depth of submucosal invasion (Sm1, Sm2 and Sm3) with Sm3 showing highest risk of lymphatic spread</li> </ul>"},{"location":"endoscopy/haggitt/#resection-margins","title":"Resection Margins","text":"<ul> <li>Resection margin of &gt;2mm thought to be ideal</li> <li>&lt;1mm resection margin - 20-33% recurrence rate</li> <li>1mm or more - 0-2% recurrence rate</li> </ul>"},{"location":"endoscopy/haggitt/#references","title":"References","text":"<ol> <li>Joint Hospital Surgical Grand Round 18 Apr 2009, Malignant Rectal Polyp, Dr Kit-wai Lai, Department of Surgery, Tuen Mun Hospital</li> <li>Aarons, Cary B et al. \u201cManagement of malignant colon polyps: current status and controversies.\u201d World journal of gastroenterology vol. 20,43 (2014): 16178-83. doi:10.3748/wjg.v20.i43.16178</li> <li>Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, Uchida Y. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38:1286\u20131295</li> <li>Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985 Aug;89(2):328-36.</li> </ol>"},{"location":"endoscopy/ibd_scoring/","title":"IBD Scoring","text":"<p>IBD Scoring Cheat Sheet.pdf</p>"},{"location":"endoscopy/polyp_resection_strategy/","title":"Polyp Resection Strategy","text":"<p>Created: 17 July 2024</p> <p>Last Updated: 17 July 2024</p> Lesion type Lesion size Strategy SSL Any size Piecemeal cold snare with good margin of normal tissue. No requirement   for snare tip soft coagulation to margins or clipping of right sided lesions SSL with dysplastic nodule Up to 2cm Lift, hot snare EMR, cut current (i.e. treat as for adenoma) SSL with dysplastic nodule &gt;2cm Refer to complex polyp MDT for resection on EMR list. Only tattoo if   very subtle lesion Pedunculated adenoma Any size Hot snare, coagulation current. Consider pre-injection of stalk with   adrenaline for large stalks. Consider clipping of stalk post resection Sessile adenoma with regular surface pattern 1cm or less Cold snare with good margin of normal tissue. Cold snaring and   confirmation of full clearance is easiest after lifting Sessile adenoma with regular surface pattern and good access 1-2cm Lift, hot snare EMR, cut current. Snare tip soft coagulation not   generally needed for lesions less than 2cm as there is no evidence base for   this Sessile adenoma with regular surface pattern &gt;2cm Refer to complex polyp MDT for resection on EMR list. No requirement   to tattoo as these lesions will not be missed Sessile adenoma with poor access Any size Refer to complex polyp MDT for discussion. Consider tattoo if lesion   difficult to find Sessile adenoma with areas of irregular or absent surface pattern Any size Biopsy irregular surface areas, tattoo in case resection required,   refer to complex polyp MDT for discussion Recurrent adenoma in previous resection site Any size Refer to complex polyp MDT for discussion Cancer Any size Biopsy, tattoo, arrange cross sectional imaging, refer colorectal MDT"},{"location":"endoscopy/ugi_bleeding/","title":"UGI Bleed Risk Scoring","text":"<p>Date: 28-10-2019</p>"},{"location":"endoscopy/ugi_bleeding/#score-calculators","title":"Score Calculators","text":"<ol> <li>Glasgow Blatchford Score</li> <li>Rockall Complete Score</li> <li>Rockall Pre-Endoscopy Score</li> <li>AIMS65</li> </ol>"},{"location":"endoscopy/ugi_bleeding/#rockall-score","title":"Rockall Score","text":"<ul> <li>Pre-endoscopic score (ignore last 2 rows in figure below) of 0 considered low risk</li> <li>Completed scores of &lt;2 considered low risk</li> </ul> <p>Completed scores and outcomes:</p> Score Rebleed Rate Mortality Rate 0 4.9% 0% 1 3.4% 0% 2 5.3% 0.2% 3 11.2% 2.9% 4 14.1% 5.3% 5 24.1% 10.8% 6 32.9% 17.3% 7 43.8% 27% 8 or more 41.8% 41.1%"},{"location":"endoscopy/ugi_bleeding/#glasgow-blatchford-score","title":"Glasgow Blatchford Score","text":"<ul> <li>Modeled on Glasgow population in 1997</li> <li>Pre-endoscopy scoring system</li> <li>Scores of 0-1 low risk of intervention</li> <li>Helps predict who can be safely managed as outpatient</li> <li>Coffee ground vomiting not used in score (not a good predictor)</li> <li>Not validated for inpatient use</li> <li>Score &gt;0 do not imply need for admission</li> </ul>"},{"location":"endoscopy/ugi_bleeding/#aims65","title":"AIMS65","text":"<ul> <li>Simpler scoring method</li> <li>Max score 5</li> <li>2 or more is high risk</li> <li>Low AIMS65 not validated for discharge</li> <li>Used to predict mortality only; correlation to rebleeding rates, endoscopic findings unknown</li> </ul> Risk Factor Score Albumin &lt;30g/L 1 INR &gt;1.5 1 Altered Mental Status 1 SBP &lt;90 1 Age &gt;65 1"},{"location":"endoscopy/ugi_bleeding/#comparing-scores","title":"Comparing Scores","text":"<ul> <li>Comparison shows GBS to be more accurate at predicting intervention or death compared to AIMS65 or Rockall (AUROC of 0.86 vs 0.66 for Rockall and 0.68 for AIMS65)(2)</li> </ul> <p>Rockall vs GBS below</p> <p></p> <p>Comparison for need for any intervention (transfusion, endoscopic treatment, interventional radiology or surgery) or 30-day mortality below</p> <p></p>"},{"location":"endoscopy/ugi_bleeding/#references","title":"References","text":"<ol> <li>Rockall TA, Logan RF, Devlin HB, et al Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-321.</li> <li>Stanley Adrian J, Laine Loren, Dalton Harry R, Ngu Jing H, Schultz Michael, Abazi Roseta et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study BMJ 2017; 356 :i6432</li> <li>Original Glasgow-Blatchford Score Paper</li> <li>AIMS 65 Paper 2011</li> </ol>"},{"location":"liver/acalculous_cholecystitis/","title":"Acalculous Cholecystitis","text":"<p>Date: 30-10-2019</p> <ul> <li>Most often occurs in critically ill patients (trauma, shock, burns, sepsis, TPN, prolonged fasting)</li> <li>Difficult to diagnose pain, fever, deranged LFTs not specific</li> <li>Acute necroinflammatory disease of the gallbladder in the absence of gallstones</li> <li>Complications: gangrene, perforation, empyema</li> <li>High mortality - typically 30%, ranges from 10-90% depending on diagnostic stage</li> </ul>"},{"location":"liver/acalculous_cholecystitis/#diagnosis","title":"Diagnosis","text":"<ul> <li>Usually radiological via ultrasound or CT</li> <li>Diagnostic laparoscopy sometimes used if above modalities unclear</li> </ul>"},{"location":"liver/acalculous_cholecystitis/#treatment","title":"Treatment","text":"<ul> <li>Cholecystostomy and/or cholecystectomy</li> <li>Tube removed at 3 weeks usually</li> </ul>"},{"location":"liver/acalculous_cholecystitis/#read-more","title":"Read More","text":"<ol> <li>Acute Acalculous Cholecystitis: A Review</li> </ol>"},{"location":"liver/gallbladder_polyps/","title":"Gallbladder Polyps in PSC","text":"<p>Date: 26-10-2019</p> <ul> <li>Gallbladder polyps in PSC have increased malignant potential compared to non-PSC patients</li> <li>Various studies show that between 14-50% of resected polyps are malignant (quality of evidence low)</li> <li>BSG 2019 guidelines suggests annual USS and polyps should be referred to HPB MDT (strength of recommendation weak, quality of evidence low)</li> <li>EASL and AASLD recommend resection of gallbladder polyps in PSC regardless of size (this is controversial - ESGAR, EAES, ESGE, EFISDS don't agree)</li> </ul>"},{"location":"liver/gallbladder_polyps/#european-guidelines","title":"European Guidelines","text":""},{"location":"liver/gallbladder_polyps/#references","title":"References","text":"<ol> <li>Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019;68:1356-1378.</li> <li>Wiles, Rebecca et al. \u201cManagement and follow-up of gallbladder polyps : Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery\u2009-\u2009European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE).\u201d European radiology vol. 27,9 (2017): 3856-3866. doi:10.1007/s00330-017-4742-y</li> </ol>"},{"location":"liver/hepatitis_c/","title":"Hepatitis C","text":"<ul> <li>RNA virus</li> <li>Chronic hep C infection leads to cirrhosis</li> <li>Extra-hepatic manifestations: cryoglobulinaemia, porphyria cutanea tarda, lichen planus, lymphoproliferative disorders, type 2 diabetes, accelerated cardiovascular disease</li> </ul>"},{"location":"liver/hepatitis_c/#goal-of-therapy","title":"Goal of Therapy","text":"<ul> <li>SVR 12 or 24 weeks - undetectable HCV RNA</li> </ul>"},{"location":"liver/liver_anatomy/","title":"Liver Anatomy","text":"<p>Date: 26-10-2019</p>"},{"location":"liver/liver_anatomy/#coinaud-classification","title":"Coinaud Classification","text":"<ul> <li>Divides liver into eight functionally indepedent segments</li> <li>Each segment has vascular inflow, outflow and biliary drainage</li> <li>Centre: Branch of portal vein, hepatic artery and bile duct</li> <li>Periphery: Hepatic veins</li> </ul>"},{"location":"liver/liver_anatomy/#division","title":"Division","text":"<ul> <li>Right hepatic vein divides right lobe into anterior and posterior</li> <li>Middle hepatic vein divides liver into right and left hemiliver</li> <li>Falciform ligament divides left lobe into IV vs II+III</li> <li>Portal vein divides into upper and lower segments</li> </ul>"},{"location":"liver/liver_anatomy/#helpful-tip","title":"Helpful Tip","text":""},{"location":"liver/liver_anatomy/#trivia","title":"Trivia","text":"<ul> <li>First described by French Surgeon Claude Couinaud in 1957</li> </ul>"},{"location":"liver/liver_anatomy/#references","title":"References","text":"<p>Image Source</p> <p>Case Courtesy of Dr Craig Hacking, Radiopaedia.org. From the case ID: 62592</p> <p>More Details</p>"},{"location":"liver/pregnancy_and_liver_disease/","title":"Pregnancy-Related Liver Disease","text":"<p>Date: 30-10-2019</p> <ul> <li>Around 3% of pregnancies are complicated by some form of liver disease</li> <li>Physiological changes in pregnancy: Raised ALP in 3rd trimester, lower albumin, spider naevi, palmar erythema, reduced gallbladder motility (increased risk of gallstones)</li> </ul> <p>Pregnancy and liver disease can be divided into 3 subclasses:</p> <ol> <li>Pregnancy-related liver disease</li> <li>Non-pregnancy related liver disease eg. hepatitis etc.</li> <li>Pre-existing chronic liver disease</li> </ol>"},{"location":"liver/pregnancy_and_liver_disease/#early","title":"Early","text":""},{"location":"liver/pregnancy_and_liver_disease/#hyperemesis-gravidarum","title":"Hyperemesis Gravidarum","text":"<ul> <li>Intractable nausea and vomiting</li> <li>Usually 9-20 weeks</li> <li>Assoc with abnormal LFTs in approx 50%</li> <li>Complicates 0.3-2% of pregnancies</li> <li>Aim to rule out other causes of deranged LFTs</li> </ul>"},{"location":"liver/pregnancy_and_liver_disease/#late","title":"Late","text":""},{"location":"liver/pregnancy_and_liver_disease/#intrahepatic-cholestasis-of-pregnancy","title":"Intrahepatic Cholestasis of Pregnancy","text":"<ul> <li>Abnormal biliary transport over cannalicular membrane (multifactorial cause)</li> <li>Late 2nd to 3rd trimester and resolves within 4 weeks of delivery</li> <li>Main symptom is pruritus</li> <li>Other symptoms: malabsorption, steatorrhoea, jaundice</li> <li>Measure serum bile acid levels - &gt;40micromols correlated with adverse outcomes</li> <li>Rx UDCA 15mg/kg/day; rifampicin 2nd line</li> <li>40-70% recurrence in subsequent pregnancies</li> <li>If derangement persists beyond 3 months post-delivery should be further investigated</li> <li>Generally benign for mother but may be associated with poor perinatal outcomes for the foetus</li> </ul>"},{"location":"liver/pregnancy_and_liver_disease/#acute-fatty-liver-of-pregnancy","title":"Acute Fatty Liver of Pregnancy","text":"<ul> <li>Microvesicular fatty infiltration of hepatocytes</li> <li>Medical and obstetric emergency as is associated with mortality</li> <li>3rd trimester</li> <li>1 in 7000 to 1 in 16000 pregnancies</li> <li>?related to mitochondrial dysfunction</li> <li>Initial presentation non-specific but can progress rapidly to acute liver failure</li> <li>Deranged LFTs usually 300-500 for aminotransferases and raised bilirubin</li> <li>Hypoglycaemia is characteristic and carries a poor prognosis</li> <li>DIC in 10%</li> <li>Diagnosis based on clinical, lab findings, Swansea criteria and exclusion of other liver diseases</li> <li>Main differential is HELLP syndrome (signs of liver failure more common in AFLP)</li> <li>Rx early delivery and supportive care</li> </ul>"},{"location":"liver/pregnancy_and_liver_disease/#hellp-syndromepre-eclampsia","title":"HELLP Syndrome/Pre-Eclampsia","text":"<ul> <li>HELLP is variant of severe pre-eclampsia (12%)</li> <li>Haemolysis, elevated liver enzymes and low platelets</li> <li>Usually presents with abdominal pain, nausea/vomiting, hypertension, proteinuria</li> <li>DIC can be seen in severe cases</li> <li>Histopath changes: periportal haemorrhage, hepatocyte necrosis, sinusoidal fibrin deposition</li> <li>Rx: Delivery</li> </ul>"},{"location":"liver/pregnancy_and_liver_disease/#references","title":"References","text":"<ol> <li>Liver Disease During Pregnancy: A Challenging Clinical Issue</li> <li>Pregnancy-associated liver disease: a curriculum-based review</li> </ol>"},{"location":"luminal/coeliac/","title":"Coeliac Disease","text":"<p>Date: 23-10-2019</p>"},{"location":"luminal/coeliac/#genetics","title":"Genetics","text":"<ul> <li>Very strong association with HLA-DQ2.5 (&gt;90% of CD patients). DR3, DQ2 positivity</li> <li>Remainder are HLA-DQ8</li> </ul>"},{"location":"luminal/coeliac/#diagnosis","title":"Diagnosis","text":"<ul> <li>Serology: anti-TTG IgA</li> <li>Biopsy remains gold standard as not all serology kits are reliable</li> <li>2% of patients are IgA deficient</li> <li>HLA testing has high negative predictive value in unclear cases</li> <li>Vilous atrophy may be patchy therefore at least four biopsies recommended</li> </ul>"},{"location":"luminal/coeliac/#pathology","title":"Pathology","text":"<ul> <li>Increased intraepithelial lymphotcytes, crypt hyperplasia, villous atrophy</li> <li>Marsh classification</li> <li>Note villous atrophy is not specific for coeliac</li> </ul> <p>Pathology report:</p> <ul> <li>Number of biopsies</li> <li>Architecture: Normal, partial, subtotal or total villous atrophy</li> <li>Lamina propria features: lymphocytes, plasma cells, eosinophils</li> <li>Presence of Brunner's glands</li> <li>Crypt hyperplasia</li> <li>Villous height:crypt depth ratio (3:1)</li> <li>Evaluation of intraepithelial lymphocytes</li> </ul> <p></p> <p></p>"},{"location":"luminal/coeliac/#differential-diagnoses-of-lymphocytic-duodenosis-and-villous-atrophy","title":"Differential diagnoses of lymphocytic duodenosis and villous atrophy","text":"<ul> <li>Infection eg H. Pylori, CVID, drugs, neoplasia</li> </ul>"},{"location":"luminal/coeliac/#extra-intestinal-manifestations","title":"Extra-Intestinal Manifestations","text":"<ul> <li>Dermatitis herpetiformis (diagnosed by IgA in perilesional skin, rx dapsone)</li> </ul>"},{"location":"luminal/coeliac/#follow-up","title":"Follow-up","text":"<ul> <li>Annual FBC, LFTs, folate/B12, ferritin, TFTs, anti-tTG</li> <li>Assess tTG at 1 year - should normalise if sticking to gluten-free diet</li> <li>Need for long-term follow-up is controversial</li> <li>Increased risk of OP - check Ca, ALP, vit D - DEXA in patients after 1 year of GFD if over age of 55 or additional risk factors of OP</li> <li>Can get functional hyposplenism - pneumococcal, haemophilus, meningococcus and influenza vaccinations</li> <li>If non-adherent - review with dietician</li> </ul>"},{"location":"luminal/coeliac/#non-responsive-cd","title":"Non-responsive CD","text":"<ul> <li>Review diagnosis</li> <li>Review adherence</li> <li>If adherent consider repeat OGD, colonoscopy, elastase and TFTs, small bowel imaging</li> </ul>"},{"location":"luminal/coeliac/#refractory-cd","title":"Refractory CD","text":"<ul> <li>Defined as persistent or recurrent malabsorptive despite a strict GFD for more than 12 months in the absence of other causes of villous atrophy or malignant complications</li> <li>Type 1 - Monoclonal T cells</li> <li>Treatment in type 1 - no standard Rx, steroids, budesonide, azathioprine, elemental diets used</li> <li>Type 2 - Aberrant T cells (Loss of CD3/CD8) - poorer prognosis, increased risk of transformation to EATL</li> <li>Ulcerative jejunoileitis should raise suspicion for lymphoma</li> </ul>"},{"location":"luminal/coeliac/#malignancy","title":"Malignancy","text":"<ul> <li>EATL - Rare lymphoma associated with RCD2, 5 year survival &lt;20%</li> <li>Association with B cell lymphoma and small intestinal adenocarcinoma</li> </ul>"},{"location":"luminal/coeliac/#references","title":"References","text":"<p>BSG Coeliac Guidelines 2014</p> <p>Image Source</p>"},{"location":"luminal/eoe/","title":"Eosinophilic Oesophagitis","text":"<p>Date: 25-10-2019</p>"},{"location":"luminal/eoe/#introduction","title":"Introduction","text":"<p>EOE was first recognised in the late 1970s. Main cause of dysphagia and food bolus in children and young adults.</p>"},{"location":"luminal/eoe/#definition","title":"Definition","text":"<p>Chronic, local immune-mediated oesophageal disease with symptoms of oesophageal dysfunction and eosinophil-predominant inflammation following exclusion of other causes of eosinophilia.</p> <p>(PPI-responsive oesophageal eosinophilia now dropped from definition - PPI therapy no longer criteria for EOE diagnosis)</p> <p>Patients achieving remission on PPI are part of the EOE continuum.</p>"},{"location":"luminal/eoe/#epidemiology","title":"Epidemiology","text":"<ul> <li>Incidence: 1-20 per 100 000 population</li> <li>Prevalence: 13-49 per 100 000 population</li> <li>23-50% of patients with dysphagia and food bolus</li> <li>Male gender strong risk factor</li> <li>Peak age 30-50 years old</li> <li>Association with rhinitis, asthma, eczema (remains unproven that atopy increases risk of EOE)</li> </ul>"},{"location":"luminal/eoe/#diagnosis","title":"Diagnosis","text":"<ul> <li>At least 6 biopsies from different locations</li> <li>Greater than 15 eosinophils per high power field</li> </ul>"},{"location":"luminal/eoe/#treatment","title":"Treatment","text":"<ul> <li>PPI eg omeprazole 20-40mg BD - 50% histologic remission (&lt;15 eosinophils pHPF); if responds recommend long-term (70-80% maintain remission at 1 year)</li> <li>Topical steroids (side effect 10-15% candidiasis) - Swallowed fluticaasone (2 puffs QDS) previously, now oral budesonide viscous 1mg BD</li> <li>Allergy testing of little utility</li> <li>Dilatation is generally safe (perforation rate 0.3%), post-procedure chest pain in approx 75%</li> <li>Systemic steroids NOT recommended</li> </ul>"},{"location":"luminal/eoe/#follow-up","title":"Follow-up","text":"<ul> <li>Endoscopy 6-12 weeks post treatment is recommended</li> </ul>"},{"location":"luminal/eoe/#references","title":"References","text":"<ol> <li>UEG Guidelines 2017</li> </ol>"},{"location":"luminal/ghg/","title":"Giant Hypertrophic Gastropathy","text":"<p>Date: 26-10-2019</p>"},{"location":"luminal/ghg/#introduction-menetriers-disease","title":"Introduction (M\u00e9n\u00e9trier's Disease)","text":"<ul> <li>Rare disease</li> <li>Incidence &lt;1 per 200 000. Age&lt;10 or adult 30-60 years with peak at 55. Male preponderance.</li> <li>Oedema, hypoproteinaemia and achlorhydria</li> <li>Protein-losing enteropathy</li> <li>Described by French pathologist M\u00e9n\u00e9trier in 1888</li> <li>One of two most understood hypertrophic gastropathies (the other is Zollinger-Ellison)</li> </ul>"},{"location":"luminal/ghg/#diagnostic-tests","title":"Diagnostic tests","text":"<ul> <li>Large tortous folds in gastric fundus and body</li> <li>Histology shows massive foveolar hyperplasia</li> <li>Radiology and endoscopy with deep mucosal biopsies</li> <li>24h pH manometry shows hypochlorhydria/achlorhydria</li> <li>Gastrin levels normal</li> </ul>"},{"location":"luminal/ghg/#treatment","title":"Treatment","text":"<ul> <li>Cetuximab (EGFR monoclonal antibody) is first-line</li> <li>High protein diet</li> <li>PPI</li> <li>Gastrectomy if severe persistent disease with substantial protein loss</li> </ul>"},{"location":"luminal/ghg/#references","title":"References","text":"<p>GHG Secretory Study</p> <p>Radiopaedia</p> <p>Image source</p>"},{"location":"luminal/sibo/","title":"Small Intestinal Bacterial Overgrowth","text":"<p>Date: 25-10-2019</p>"},{"location":"luminal/sibo/#diagnosis","title":"Diagnosis","text":"<ul> <li>Not straightforward</li> <li>Low B12, raised red cell folate are clues</li> <li>May have slightly raised CRP</li> <li>Often co-existent with other GI diseases eg. IBD</li> </ul>"},{"location":"luminal/sibo/#diagnostic-tests","title":"Diagnostic tests","text":"<ul> <li>Culture of small bowel aspirate from endoscopy</li> <li>Alternative is hydrogen breath testing following carbohydrate load (hydrogen and methane are not produced by human cells), poor sensitivity and specificity</li> </ul>"},{"location":"luminal/sibo/#treatment","title":"Treatment","text":"<ul> <li>Sometimes treated empirically due to limited availability of tests</li> <li>1-2 weeks of antibiotics eg rifaximin, vancomycin (gut-selective)</li> <li>Limited evidence</li> </ul>"},{"location":"luminal/sibo/#references","title":"References","text":"<ol> <li>BSG</li> </ol>"},{"location":"nutrition/gut_peptides/","title":"Gut Peptides","text":"<p>Date: 29-10-2019</p>"},{"location":"nutrition/gut_peptides/#ghrelin","title":"Ghrelin","text":"<ul> <li>Produced by enteroendocrine cells in the oxyntic glands of the stomach and upper intestine</li> <li>Ligand for the growth hormone stimulatory receptor (GHS-R)</li> <li>Rises before meals and falls rapidly when food is eaten (High levels in fasting states)</li> <li>Ghrelin stimulates food intake</li> <li>Crosses blood brain barrier</li> </ul>"},{"location":"nutrition/gut_peptides/#gastrin","title":"Gastrin","text":"<ul> <li>Produced by G cells in antrum, duodenum and pancreas</li> <li>Released when food enters the stomach</li> <li>Stimulates release of acid by parietal cells</li> <li>Stimulates release of pepsinogen by chief cells</li> <li>Induces pancreatic secretions and gallbladder emptying</li> </ul> <p>!!! info     Pathological in Zollinger-Ellison syndrome (gastrinoma usually of the duodenum or pancreas)</p> <p>!!! tip     Levels increased by PPI use and autoimmune gastritis (can be used to check compliance)</p>"},{"location":"nutrition/gut_peptides/#secretin","title":"Secretin","text":"<ul> <li>Produced by S cells in duodenum</li> <li>Regulates pH of duodenum by inhibiting parietal cells and stimulating bicarbonate from ductal cells of pancreas</li> <li>Stimulates bile production</li> <li>Role in water regulation</li> </ul>"},{"location":"nutrition/gut_peptides/#vasoactive-intestinal-peptide","title":"Vasoactive Intestinal Peptide","text":"<ul> <li>Produced by many tissues - gut, pancreas, brain</li> <li>Induces smooth muscle relaxation (LES, stomach, gallbladder)</li> <li>Stimulates water and electrolyte secretion in small intestine</li> <li>Similar role to secretin - inhibits gastric acid, stimulate bicarbonate</li> <li>Also found in the heart - coronary vasodilatation, positive ionotropic and chronotropic effect</li> </ul>"},{"location":"nutrition/gut_peptides/#vipoma","title":"VIPoma","text":"<ul> <li>90% originate from non-islet cells of pancreas, incidence 1 in 10 million/year</li> <li>Associated with MEN1 syndrome, 50-75% malignant at presentation</li> <li>Symptoms: Profound watery and chronic diarrhoea with low K, low Cl, acidosis, flushing, hypotension, high Ca (VIP stimulates bone resorption), high glucose (VIP stimulates glycogenolysis), lethagy, muscle weakness, nausea, vomiting, crampy abdominal pain</li> <li>Diagnosis: Measure VIP levels, CT, MRI, somatostatin receptor scintigraphy</li> <li>Management: Octreotide blocks action of VIP, manages symptoms; Surgery if possible, alternative is peptide receptor radionuclide therapy (attach radionuclide to octreotide)</li> </ul>"},{"location":"nutrition/gut_peptides/#cck","title":"CCK","text":"<ul> <li>Produced by I cells in upper intestine</li> <li>Slows gastric emptying, mediates intestinal motility</li> <li>Stimulates pancreatic and gallbladder secretions</li> <li>Levels rise rapidly when food enters intestine within 15 minutes</li> <li>Falls with meal termination</li> <li>Exogenous CCK inhibits food intake by reducing meal size and duration</li> </ul>"},{"location":"nutrition/gut_peptides/#glucagon-and-amylin","title":"Glucagon and Amylin","text":"<ul> <li>Similar levels profile to CCK</li> <li>Amylin centrally mediated</li> <li>Glucagon peripherally mediated in the liver</li> </ul>"},{"location":"nutrition/gut_peptides/#pancreatic-polypeptide","title":"Pancreatic Polypeptide","text":"<ul> <li>Islet of Langerhans</li> <li>Reduces food intake via Y4 receptor in brainstem and hypothalamus</li> <li>PP levels rise in response to food intake</li> </ul>"},{"location":"nutrition/gut_peptides/#glp-1","title":"GLP-1","text":"<ul> <li>Produced by L cells in distal intestine (co-secreted with peptide YY)</li> <li>Slower time profile - lasting several hours after a meal</li> <li>Inhibits food intake - reduces food size, increases satiety ratio (but limited effect due to quick degradation by DPP4)</li> <li>Stimulates insulin release</li> <li>Continous analogues resistant to DPP4 degradation lead to reduced appetite, body weight and improved glycaemic control</li> </ul>"},{"location":"nutrition/gut_peptides/#peptide-yy","title":"Peptide YY","text":"<ul> <li>Produced by L cells in distal intestine</li> <li>Slower time profile - lasting several hours after a meal</li> <li>Two forms - PYY 1-36 and PYY 3-36</li> </ul>"},{"location":"nutrition/gut_peptides/#leptin","title":"Leptin","text":"<ul> <li>Levels rise with increased amount of adipose tissue</li> <li>Secreted by adipocytes</li> <li>Diurnal variation of levels, peaks at night</li> <li>Resistance to leptin in obese subjects</li> </ul>"},{"location":"nutrition/gut_peptides/#references","title":"References","text":"<ol> <li>Gut peptides in the control of food intake</li> <li>The Gut Hormones in Appetite Regulation</li> <li>BMJ Best Practice VIPoma</li> </ol>"},{"location":"nutrition/vitamin_b12/","title":"Vitamin B12 Metabolism","text":"<ul> <li>Water soluble vitamin</li> <li>Important cofactor for DNA synthesis - red cell and neurological function</li> <li>Only produced by certain bacteria and archaea (single-cell organisms)</li> </ul>"},{"location":"nutrition/vitamin_b12/#absorption-pathway","title":"Absorption Pathway","text":"<ul> <li>First binds to haptocorrin (from salivary glands, protects B12 from acid degradation)</li> <li>Intrinsic factor from parietal cells in stomach and bound B12 enter duodenum</li> <li>Pancreatic proteases free B12 from haptocorrin and allow binding to IF</li> <li>Absorbed in terminal ileum</li> <li>Released from IF and binds to transcobalamin</li> <li>Stored in the liver</li> </ul> <p>!!! info     Some B12 is filtered out by the kidney and recovered in the renal tubules by megalin</p>"},{"location":"nutrition/vitamin_b12/#daily-requirements","title":"Daily requirements","text":"<p>Adults: 2.4mcg/day Pregnant: 2.6mcg/day</p>"},{"location":"nutrition/vitamin_b12/#pernicious-anaemia","title":"Pernicious Anaemia","text":"<ul> <li>Autoimmune atrophic gastritis</li> <li>Cause for 20-50% of B12 deficiency</li> <li>Anti-IF and anti-GPC antibodies (combined performance 73% sensitivity 100% specificity)</li> <li>Associated with autoimmune thyroid disease (40%), T1DM (5-10%)</li> <li>Onset is usually slow and insidious</li> <li>Symptoms relating to anaemia, neurological symptoms much rarer</li> <li>Differential diagnoses: dietary deficiency, other disorders impairing absorption eg Crohn's, post-surgery</li> <li>Increased risk of gastric adenocarcinoma (annual incidence 0.1-0.5%)</li> </ul>"},{"location":"nutrition/vitamin_b12/#trivia","title":"Trivia","text":"<ul> <li>B12 is produced industrially by fermentation of certain strains of bacteria</li> <li>4 companies produce the world's supply</li> </ul>"}]}